Literature DB >> 16508734

Timing of significant adverse events is essential information during early development of new drugs.

Ichinosuke Hyodo.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16508734     DOI： 10.1007/s10147-005-0521-x

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN： 1341-9625            Impact factor:   3.402


× No keyword cloud information.
  2 in total

1.  A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors.

Authors:  Toshiaki Saeki; Shigemitsu Takashima; Masanori Terashima; Atsushi Satoh; Masakazu Toi; Akihiko Osaki; Tetsuya Toge; Shinji Ohno; Naohiro Nomura; Yoshio Fukuyama; Wasaburo Koizumi; Tetsuo Taguchi
Journal:  Int J Clin Oncol       Date:  2005-02       Impact factor: 3.402

2.  Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.

Authors:  D R Budman; N J Meropol; B Reigner; P J Creaven; S M Lichtman; E Berghorn; J Behr; R J Gordon; B Osterwalder; T Griffin
Journal:  J Clin Oncol       Date:  1998-05       Impact factor: 44.544
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.